Table 3.
CAM Presentation, Management, and Outcomes, Grouped by Setting
| Variable | Metropolitan Cairo (n = 15) | Upper Egypt (n = 11) | Total (n = 26) |
|---|---|---|---|
| Onset | |||
| Coexisting with COVID-19 | 8 (53.3%) | 7 (63.6%) | 15 (57.7%) |
| After recovery from COVID-19 | 7 (46.7%) | 4 (36.4%) | 11 (42.3%) |
| Interval: COVID-19 to CAM (days) | |||
| Median (IQR) | 30 (20–60) | 15 (15–30) | 20.5 (15–30) |
| Initial complaint | |||
| Facial Swelling | 10 (66.7%) | 3 (27.3%) | 13 (50%) |
| Lid Swelling | 3 (20%) | 4 (36.3%) | 7 (26.9%) |
| Skin blackish discoloration | 2 (13.3%) | 1 (9.1%) | 3 (11.5%) |
| Nasal Obstruction | 0 (0%) | 2 (18.2%) | 2 (7.7%) |
| Diminution of vision | 0 (0%) | 1 (9.1%) | 1 (3.9%) |
| CDVA on presentation | |||
| 20/40 (0.5) or better | 3 (20%) | 0 (0%) | 3 (11.5%) |
| 20/200 (0.1) - 20/40 (0.5) | 0 (0%) | 1 (9.1%) | 1 (3.9%) |
| Fair on bedside assessment | 3 (20%) | 0 (0%) | 3 (11.5%) |
| Light Perception | 3 (20%) | 0 (0%) | 3 (11.5%) |
| No Light Perception (Lost) | 6 (40%) | 10 (90.9%) | 16 (61.6%) |
| Surgical intervention | |||
| Yes | 7 (46.7%) | 10 (90.9%) | 17 (65.4%) |
| No | 8 (53.3%) | 1 (9.1%) | 9 (34.6%) |
| Final outcome | |||
| Recovery and Discharge | 9 (60%) | 5 (45.5%) | 14 (53.8%) |
| Death | 6 (40%) | 6 (54.5%) | 12 (46.2%) |
Abbreviations: COVID-19, coronavirus disease 2019; CAM, COVID-associated mucormycosis; IQR, interquartile range; CDVA, corrected distance visual acuity.